# Gastrointestinal Neoplasms FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/gastrointestinal-neoplasms

> 4 upcoming FDA catalysts in gastrointestinal Neoplasms: velzatinib (GSK) on Nov 2027 to Feb 2028 (topline data readout); velzatinib (GSK) on November 2027 (primary completion); velzatinib - subject to usan approval (GSK) on May to Aug 2028 (topline data readout); velzatinib - subject to usan approval (GSK) on May 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2027 to Feb 2028 | [Velzatinib topline data readout](https://sec-api.dev/pdufa/velzatinib) | GSK | Gastrointestinal Neoplasms | scheduled | "NCT07689201 (A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07689201)) |
| November 2027 | [Velzatinib primary completion](https://sec-api.dev/pdufa/velzatinib) | GSK | Gastrointestinal Neoplasms | scheduled | "NCT07689201 (A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07689201)) |
| May to Aug 2028 | [Velzatinib - subject to usan approval topline data readout](https://sec-api.dev/pdufa/velzatinib-subject-to-usan-approval) | GSK | Gastrointestinal Neoplasms | scheduled | "NCT07218926 (A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218926)) |
| May 2028 | [Velzatinib - subject to usan approval primary completion](https://sec-api.dev/pdufa/velzatinib-subject-to-usan-approval) | GSK | Gastrointestinal Neoplasms | scheduled | "NCT07218926 (A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218926)) |

## Drugs

- [Velzatinib](https://sec-api.dev/pdufa/velzatinib) (GSK)
- [Velzatinib - subject to usan approval](https://sec-api.dev/pdufa/velzatinib-subject-to-usan-approval) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/gastrointestinal-neoplasms.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Gastrointestinal Neoplasms FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/gastrointestinal-neoplasms

```bibtex
@misc{secapidev_indications_gastrointestinal_neoplasms_20261116,
  title        = {Gastrointestinal Neoplasms FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/gastrointestinal-neoplasms}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_gastrointestinal_neoplasms_20261116","title":"Gastrointestinal Neoplasms FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/gastrointestinal-neoplasms","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
